April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Evisceration with Injectable Hydrogel Implant
Author Affiliations & Notes
  • Elysa A Brown
    Ophthalmology, Wake Forest Medical Center, Winston Salem, NC
  • Irina Koreen
    Ophthalmology, Wake Forest Medical Center, Winston Salem, NC
  • R. Patrick Yeatts
    Ophthalmology, Wake Forest Medical Center, Winston Salem, NC
  • Footnotes
    Commercial Relationships Elysa Brown, None; Irina Koreen, None; R. Patrick Yeatts, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 2782. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Elysa A Brown, Irina Koreen, R. Patrick Yeatts; Evisceration with Injectable Hydrogel Implant. Invest. Ophthalmol. Vis. Sci. 2014;55(13):2782.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Evisceration with implant is typically performed using solid sphere implants to reconstitute globe volume. Placement of the sphere requires large anterior and posterior scleral incisions. The development of a liquid injectable implant would permit evisceration through a small incision, such as with 20 gauge vitrectomy. The objective of this study was to determine the safety, durability, and biocompatibility of 2.5% polyacrylamide hydrogel as an injectable implant material in evisceration using a rabbit model.

Methods: The protocol was approved by the Wake Forest Institutional Animal Care and Use Committee. Thirteen adult New Zealand rabbits underwent small incision cornea-sparing evisceration of one eye with injection of 2.5% polyacrylamide hydrogel implant. Evisceration was performed through an 8 mm scleral incision 2 mm posterior to the limbus. The wound closure was completed, followed by injection of 2.5% polyacrylamide hydrogel using a 23 gauge needle to fill the globe. Rabbits were sacrificed at 2 weeks (n=1), 6 weeks (n=2), 3 months (n=3) and 6 months (n=3) to evaluate the implant volume and host reaction to the implant. Both eyes were enucleated and their anteroposterior, horizontal and vertical diameters were measured. The eviscerated eyes were then fixed in formalin and processed using routine histopathologic methods.

Results: The implant material was generally well tolerated. Extensive vascularization of the implant was noted starting at 6 weeks. There was excellent maintenance of globe volume that did not diminish over time. The relative diameters of the eviscerated eyes compared to control were 94% at two weeks (n=1), 100% at 6 weeks (n=2), 89 ± 6% (mean ± st dev) at 3 months (n=3), and 94 ± 2% at 6 months (n=3).

Conclusions: Based on our findings, injectable 2.5% polyacrylamide hydrogel may provide an alternative to the solid ocular implants currently used as standard of care in ocular evisceration. The implant material was universally well tolerated and maintained appropriate volume in the orbit for six months following surgery. Vascularization of the implant was a surprising but welcome finding, as it decreases the risk of implant infection. Future directions include evaluation of smaller incision evisceration techniques utilizing vitrectomy equipment for fragmentation and removal of ocular contents.

Keywords: 631 orbit  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.